Clinical Trial Update: A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating QLS4131 for relapsed or refractory multiple myeloma, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• QLS4131

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: NOT_YET_RECRUITING